◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Akums Drugs and Pharmaceuticals Limited (AKUMS) Financial History

Name: Akums Drugs and Pharmaceuticals Limited (AKUMS) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Akums Drugs and Pharmaceuticals Limited (AKUMS) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Delhi, India with about 7,337 employees. Its market capitalization is roughly ₹120 billion. In the fiscal year ended 2026-03-31, AKUMS reported ₹42.5B in revenue and ₹2.6B in net income.

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally.

Interactive charts & full statements →

AKUMS Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹42.5B	₹40.7B	₹40.2B	₹34.7B	—
Gross Profit	₹17.0B	₹16.1B	₹14.4B	₹11.7B	—
Operating Income (EBIT)	₹3.7B	₹3.1B	₹3.6B	₹1.9B	—
Net Income	₹2.6B	₹3.4B	(₹40M)	₹948M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AKUMS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹11.7B	₹11.6B	₹11.6B	₹10.2B	₹10.2B	—	—
Gross Profit	₹5.2B	₹5.0B	₹4.8B	₹4.2B	₹4.4B	—	—
Operating Income (EBIT)	₹1.3B	₹1.1B	₹1.1B	₹566M	₹920M	—	—
Net Income	₹1.0B	₹846M	₹663M	₹408M	₹635M	—	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AKUMS Free Cash Flow History

AKUMS Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹54.5B	₹41.1B	₹35.2B	₹32.7B	—
Total Liabilities	₹21.2B	₹10.5B	₹28.0B	₹25.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AKUMS viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

APLLTD · Alembic Pharmaceuticals Limited — ₹166 billion
4521 · Kaken Pharmaceutical Co., Ltd. — JPY 151 billion
NATCOPHARM · NATCO Pharma Limited — ₹148 billion
SUDEEPPHRM · Sudeep Pharma Limited — ₹130 billion
4534 · Mochida Pharmaceutical Co., Ltd. — JPY 116 billion
STAR · Strides Pharma Science Limited — ₹112 billion
VIYASH · Viyash Scientific Limited — ₹110 billion
SUVEN · Suven Life Sciences Limited — ₹97 billion

← AKTX All “A” companies AKW →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.